See more : KGL Resources Limited (KGLLF) Income Statement Analysis – Financial Results
Complete financial analysis of Enochian Biosciences, Inc. (ENOB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Enochian Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- NamSys Inc. (NMYSF) Income Statement Analysis – Financial Results
- Comforia Residential REIT, Inc (3282.T) Income Statement Analysis – Financial Results
- Telecom Argentina S.A. (TECO2.BA) Income Statement Analysis – Financial Results
- Azbil Corporation (YMATF) Income Statement Analysis – Financial Results
- Saha Pathanapibul Public Company Limited (SPC.BK) Income Statement Analysis – Financial Results
Enochian Biosciences, Inc. (ENOB)
About Enochian Biosciences, Inc.
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 42.77K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 121.86K | 113.50K | 123.59K | 391.42K | 366.27K | 71.71K | 18.48K | 14.53K | 32.67K | 314.64K | 0.00 | 0.00 |
| Gross Profit | -121.86K | -113.50K | -123.59K | -391.42K | -366.27K | -71.71K | -18.48K | -14.53K | 10.10K | -314.64K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 23.62% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.71M | 4.17M | 8.37M | 15.72M | 4.69M | 2.50M | 616.96K | 62.76K | 804.19K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 24.17M | 15.32M | 14.33M | 7.56M | 7.12M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 383.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 24.56M | 15.32M | 14.33M | 7.56M | 7.12M | 8.42M | 2.60M | 2.32M | 1.33M | 2.11M | 37.09K | 29.95K |
| Other Expenses | 54.37M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 81.64M | 19.60M | 22.83M | 23.40M | 11.92M | 10.92M | 3.22M | 2.39M | 2.13M | 2.11M | 37.09K | 29.95K |
| Cost & Expenses | 81.64M | 19.60M | 22.83M | 23.40M | 11.92M | 10.99M | 3.24M | 2.40M | 2.16M | 2.43M | 37.09K | 29.95K |
| Interest Income | 0.00 | 0.00 | 122.04K | 13.18K | 50.30K | 73.49K | 45.82K | 0.00 | 0.00 | 5.94K | 0.00 | 0.00 |
| Interest Expense | 1.01M | 706.96K | 372.84K | 379.61K | 104.28K | 43.00 | 143.26K | 26.26K | 2.36K | 84.55K | 497.00 | 0.00 |
| Depreciation & Amortization | 121.86K | 113.50K | 123.59K | 123.53K | 366.27K | 71.71K | 18.48K | 14.53K | 27.40K | 45.20K | 0.00 | 0.00 |
| EBITDA | -79.52M | -19.48M | -22.70M | -23.28M | -11.51M | -17.94M | -5.31M | -2.39M | -2.17M | -2.42M | -37.09K | -29.95K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,894.99% | 0.00% | 0.00% | 0.00% |
| Operating Income | -81.64M | -38.56M | -116.08M | -23.40M | -11.92M | -10.99M | -3.24M | -2.40M | -2.12M | -2.43M | -37.09K | -29.95K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,959.04% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 989.12K | -1.13M | 2.65M | -3.45M | 507.41K | -7.03M | -3.19M | 192.72K | -77.10K | -119.20K | -497.00 | 0.00 |
| Income Before Tax | -80.65M | -39.68M | -113.43M | -26.85M | -11.42M | -18.02M | -6.42M | -2.21M | -2.20M | -2.55M | -37.59K | -29.95K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,139.30% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 706.96K | 34.00 | -125.28K | 104.28K | 1.00 | -111.72K | -64.88K | -462.79K | -177.54K | 0.00 | 0.00 |
| Net Income | -80.65M | -39.68M | -113.43M | -26.72M | -11.42M | -18.02M | -6.31M | -2.14M | -1.74M | -2.37M | -37.59K | -29.95K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,057.24% | 0.00% | 0.00% | 0.00% |
| EPS | -0.84 | -0.71 | -2.16 | -0.57 | -0.25 | -0.48 | -0.29 | -0.17 | -0.18 | -0.32 | -0.01 | 0.00 |
| EPS Diluted | -0.84 | -0.71 | -2.16 | -0.57 | -0.25 | -0.48 | -0.29 | -0.17 | -0.18 | -0.32 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 96.25M | 56.27M | 52.53M | 47.17M | 46.33M | 37.55M | 21.94M | 12.27M | 9.53M | 7.50M | 5.00M | 10.44M |
| Weighted Avg Shares Out (Dil) | 96.25M | 56.27M | 52.53M | 47.17M | 46.33M | 37.55M | 21.94M | 12.27M | 9.53M | 7.50M | 5.00M | 10.44M |
Today's Biggest Pre-Market Movers: 10 Top Gainers and Losers on Thursday Morning
ENOB Stock Price Increases Over 40% Pre-Market: Why It Happened
Seraph Research Institute and Enochian BioSciences Publish a Case Report of Complete Remission of Recurrent Glioblastoma with Innovative Therapy
Enochian BioSciences to Present to Investors at the H.C. Wainwright Global Life Sciences Conference
Baby Bonds Complete Review
HD Medical obtient l'autorisation de la FDA pour HD Steth
Stopping Systemic Racism From Shortening Black Lives
Kiniksa Positive COVID-19 Data And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:KNSA)
Source: https://incomestatements.info
Category: Stock Reports